Article
Parkinson's disease: An Analysis on Key Selected Pipeline Developments and Clinical Trial Insights
IQVIA Pipeline Link and IQVIA Trial Link
Jun 04, 2025
Download

Parkinson's disease is a progressive neurodegenerative disorder primarily caused by the loss of dopamine producing neurons in the substantia nigra, a midbrain structure in the brain crucial for motor control, reward, and cognitive functions, leading to manifestation of motor symptoms called parkinsonism like tremors, bradykinesia, rigidity as well as postural instability. It was first described by James Parkinson in 1817.

By the time symptoms appear, 60% or more of these neurons are lost. The disease can also affect norepinephrine production potentially causing non-motor symptoms like fatigue and blood pressure changes. The histological hallmark of Parkinson's disease is the presence of the aggregation of alpha-synuclein into Lewy bodies within neurons.

Parkinson's disease affects 1 to 2 per 1000 individuals, with prevalence increasing to 1% of the population over 60 years. The condition is more common in men, and genetic predisposition is a factor in 5% to 10% of cases. Globally, over 10 million people are estimated to live with Parkinson's disease.

Parkinson's disease is diagnosed clinically, based on patient history, symptoms, and physical examination and an accurate diagnosis in initial stages may be difficult. While no definitive lab or imaging test exists, MRI, Dopamine Transporter Scan, and blood work may support the diagnosis or exclude conditions mimicking Parkinson's disease.

This article provides an update on current treatment options for Parkinson's disease and outlines the latest development activities including ongoing clinical trials of key experimental drugs with data sourced from IQVIA Pipeline Link and IQVIA Trial Link.

Download the article for key insights into Parkinson's treatment, trials, and pipeline innovation. Essential reading for pharma leaders seeking strategic advantage in this fast-evolving market.

Related solutions

Contact Us